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ABSTRACT
Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of
hyponatremia and autosomal dominant polycystic kidney disease (ADPKD). No liver injury has been observed with
tolvaptan treatment in healthy subjects and in non-ADPKD indications, but ADPKD clinical trials showed evidence of drug-
induced liver injury (DILI). Although all DILI events resolved, additional monitoring in tolvaptan-treated ADPKD patients is
required. In vitro assays identified alterations in bile acid disposition and inhibition of mitochondrial respiration as potential
mechanisms underlying tolvaptan hepatotoxicity. This report details the application of DILIsym software to determine
whether these mechanisms could account for the liver safety profile of tolvaptan observed in ADPKD clinical trials. DILIsym
simulations included physiologically based pharmacokinetic estimates of hepatic exposure for tolvaptan and2 metabolites,
and their effects on hepatocyte bile acid transporters and mitochondrial respiration. The frequency of predicted alanine
aminotransferase (ALT) elevations, following simulated 90/30 mg split daily dosing, was 7.9% compared with clinical
observations of 4.4% in ADPKD trials. Toxicity was multifactorial as inhibition of bile acid transporters and mitochondrial
respiration contributed to the simulated DILI. Furthermore, simulation analysis identified both pre-treatment risk factors
and on-treatment biomarkers predictive of simulated DILI. The simulations demonstrated that in vivo hepatic exposure to
tolvaptan and the DM-4103 metabolite, combined with these 2 mechanisms of toxicity, were sufficient to account for the
initiation of tolvaptan-mediated DILI. Identification of putative risk-factors and potential novel biomarkers provided insight
for the development of mechanism-based tolvaptan risk-mitigation strategies.
Key words: tolvaptan; ADPKD; DILI; DILIsym; quantitative systems pharmacology modeling.
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Tolvaptan is a selective vasopressin V2 receptor antagonist that
blocks arginine vasopressin (AVP) binding in the distal portions
of the nephron, abrogating AVP’s antidiuretic activity, and
inducing water diuresis, without concomitant electrolyte deple-
tion. Tolvaptan has been approved in several countries for the
treatment of hyponatremia and more recently, in Japan, Europe,
Canada, and Korea for the treatment of autosomal dominant
polycystic kidney disease (ADPKD).
Autosomal dominant polycystic kidney disease (ADPKD) is a
genetic disease resulting from mutation in either the PKD1 or
PKD2 genes. ADPKD is characterized by the development of
renal cysts, which can ultimately lead to renal failure.
Tolvaptan has been shown to slow ADPKD disease progression
(Torres et al., 2012); however, liver safety signals were observed
in the pivotal tolvaptan ADPKD clinical trial (Watkins et al.,
2015). Liver signals have not been observed in other patient pop-
ulations treated with tolvaptan. Understanding the mechanistic
basis of tolvaptan-mediated liver injury could support the
development of mechanism-based biomarkers for patient sus-
ceptibility and/or improved safety monitoring.
Drug-induced liver injury (DILI) is an important safety con-
cern in drug development that can lead to termination of devel-
opment programs, changes to the drug label, and market
withdrawal (Hunter et al., 1999; Kohlroser et al., 2000; Lasser
et al., 2002; Guengerich, 2011). Whereas the etiology of DILI
events is rarely known, several putative mechanisms have been
identified. For example, it has been demonstrated that com-
pounds that inhibit the bile salt export pump (BSEP), a hepatic
bile acid efflux transporter, are disproportionately represented
amongst compounds with DILI liability (Morgan et al., 2010). The
association between compounds that inhibit hepatic transport-
ers and liver safety liabilities is strengthened further by consid-
ering compound inhibition of multidrug resistance-associated
proteins (MRPs) (Morgan et al., 2013). Whereas not the primary
efflux pathway, MRP-mediated transport of bile acids to the
basolateral space may represent a compensatory pathway to
reduce bile acid accumulation when BSEP is inhibited (Ko¨ck
et al., 2014; Teng and Piquette-Miller, 2007). Although the case
for transporter-mediated effects is strong, bile acid accumula-
tion is not believed to account for all DILI cases. Other potential
mechanisms include mitochondrial dysfunction, reactive
metabolite formation, oxidative stress, and endoplasmic reticu-
lum (ER) stress. In fact, a recent analysis suggests that drugs
that demonstrate inhibition of both mitochondrial function and
BSEP are associated with a higher likelihood of severe liver
injury than those that inhibit only one of these (Aleo et al.,
2014). In vitro assays can be conducted to investigate these
potential mechanisms of toxicity for tolvaptan. However, in vitro
data alone are rarely definitive in the identification of mecha-
nisms underlying observed human hepatotoxicity.
Quantitative and Systems Pharmacology (QSP) is one
approach to evaluate in vitro data as a mechanism for in vivo
hepatotoxicity. QSP has been defined by the National Institutes
of Health as an approach to translational medicine that com-
bines computational and experimental methods to elucidate,
validate, and apply new pharmacological concepts to the devel-
opment and use of small molecule and biologic drugs (Sorger
et al., 2011).
DILIsymTM, a platform QSP model of DILI, represents liver
injury via an integrated system of sub-models including a phys-
iologically based pharmacokinetic (PBPK) sub-model, mecha-
nisms of parent compound or metabolite-mediated toxicity
(bile acid transporter inhibition, mitochondrial dysfunction, and
oxidative stress), hepatocyte population dynamics, and liver
inflammation (Shoda et al., 2014). New versions of DILIsym are
released regularly as a product of the public-private partner-
ship, the DILI-sim Initiative (www.dilisym.com). DILIsym is par-
ameterized using available experimental data, and optimized
using exemplar compounds (Howell et al., 2012; Longo et al.,
2016; Woodhead et al., 2014). DILIsym is designed to be custom-
ized to the compound of interest and serves as a unifying
framework to investigate how in vivo exposure to drugs and
their major metabolites induce mechanisms of toxicity leading
to hepatocyte death.
In this study, putative mechanisms of tolvaptan toxicity
identified through in vitro assays were evaluated for biological
plausibility as the underlying drivers of observed liver injury
using DILIsym. Further, DILIsym utilized SimPopsTM, popula-
tions of simulated individuals with variation in their underlying
biochemistry and reflecting variable compound exposure, to
explore how inter-patient variability impacted tolvaptan sus-
ceptibility to liver injury as well as the relative contribution of
different mechanisms of toxicity. Finally, susceptible and resist-
ant simulated individuals were analyzed to identify potential
pre-treatment patient risk factors and to identify potential on-
treatment biomarkers of impending liver injury. Together, the
experimental data and mathematical modeling comprising this
DILIsym QSP analysis provided a mechanistic foundation for
the observed clinical hepatotoxicity, as well as support for the
development of mechanism-based biomarkers.
MATERIALS ANDMETHODS
DILIsym overview. DILIsym has been described previously
(Bhattacharya et al., 2012; Shoda et al., 2014; Woodhead et al.,
2012). Briefly, DILIsym is a multi-scale and “middle-out” platform
focused on the liver as the primary organ of interest, which
includes detailed liver cellular dynamics and biochemistry,
extends to whole body drug distribution and systemic circulation
of mediators and biomarkers, and accounts for inter-individual
differences through variation in anthropometrics and biochemis-
try. Essential processes occur in interacting sub-models:
physiologically based pharmacokinetics (PBPK), bile acid trans-
porter inhibition, mitochondrial dysfunction, oxidative stress,
hepatocyte life cycle, and macrophage and endothelial cell life
cycles. Parameter values are informed by experimental data,
with sub-model and system-level behaviors optimized for con-
sistency with exemplar compounds (Howell et al., 2012;
Woodhead et al., 2014, 2012). Parameter solutions include those
consistent with human, rat, and mouse data (Woodhead et al.,
2012, 2014). Generally, simulations for the current study were
conducted in the baseline simulated human, and in simulated
populations (SimPops) as described previously (Longo et al., 2016;
Yang et al., 2015); tolvaptan-specific adjustments are described in
detail below.
Bile acid toxicity input data. The DILIsym bile acid sub-model rep-
resents bile acid enterohepatic circulation via bile acid trans-
porters. More specifically, hepatocyte uptake of bile acids from
blood occurs by the sodium taurocholate co-transporting poly-
peptide (NTCP) transporter. Bile acid efflux occurs via BSEP-
mediated canalicular transport and MRP3- and MRP4-mediated
basolateral transport. Drug-mediated inhibition of efflux trans-
porters can result in hepatocellular bile acid accumulation,
whereas drug-mediated NTCP inhibition can mitigate this
effect. Elevated intracellular bile acid concentrations can mech-
anistically alter mitochondrial function, leading to hepatocyte
death (Rolo et al., 2000; Schulz et al., 2013). Details of this
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representation are provided in the Supplementary File 1.
Drug-mediated inhibition of transporters can be assessed in
laboratory experiments using cells or membrane vesicles
expressing the transporter of interest. Importantly, the hepato-
toxic potential of transporter inhibition can be influenced by
type of inhibition (eg, competitive vs non-competitive) as well
as strength of inhibition (Woodhead et al., 2014). Inhibition type
can be determined from experimental Ki data. For the parame-
terization of tolvaptan, Ki data were available characterizing
inhibition of BSEP by tolvaptan [molecular weight (MW)¼ 448.
94 g/mol] and 2 metabolites, DM-4103 (MW¼ 478.92 g/mol) and
DM-4107 (MW¼ 480.94 g/mol). IC50 values for tolvaptan and the
metabolites were available for NTCP (Slizgi et al., 2016).
Mitochondrial dysfunction input data. The DILIsym mitochondria
sub-model represents mitochondrial bioenergetics leading to
adenosine triphosphate (ATP) production in hepatocytes.
Compounds may induce mitochondrial dysfunction by inhibit-
ing the electron transport chain (ETC), by inhibiting the mito-
chondrial F1FO ATPase, or by uncoupling mitochondrial
respiration from mitochondrial ATP synthesis. Compound
effects on hepatocyte mitochondrial function can be assessed
in laboratory experiments by measuring hepatocyte respiration
following culture with the compound in a Seahorse XF Analyzer
(Seahorse Bioscience, MA) (Nadanaciva et al., 2012). For the
parameterization of tolvaptan, data were obtained for the
inhibition of mitochondrial respiration by tolvaptan, DM-4103,
and DM-4107 (Figure 1). Experimental details are provided in
Supplementary File 2. A companion mechanistic mathematical
model, MITOsymTM, which simulates in vitro hepatocellular res-
piration was designed to reproduce data obtained via the
Seahorse assay for the purposes of deriving parameters charac-
terizing compound induced mitochondrial dysfunction (Yang
et al., 2014). Importantly, the compound concentration driving
an intracellular response (ie, mitochondrial respiration) may
not be equivalent to the nominal media concentration reported
in the assay protocol (Groothuis et al., 2015), where the nominal
media concentration is defined as the reported (but not meas-
ured) concentration of compound in the media. To more closely
describe the relationship between concentration at the site of
action and effect, the intracellular concentration in the HepG2
cells used in the XF Analyzer experiments was estimated using
the DILIsym PBPK simulation results; the simulated liver:-
plasma concentration ratio was assumed to approximate the
concentration ratio between the hepatocyte and the media,
thus providing a scaling factor to convert the nominal media
concentration to an estimated intracellular concentration. The
MITOsym optimization was conducted against both the nomi-
nal compound concentration and the estimated intracellular
compound concentration. Because DILIsym seeks to represent
the in vivo response, the parameters derived from the estimated
intracellular compound concentration were selected for transla-
tion to in vivo DILIsym parameters.
Reactive oxygen species input data. The DILIsym oxidative stress
sub-model represents the generation of reactive oxygen species
(ROS) in response to compound exposure. ROS accumulation can
lead to hepatocyte apoptosis or necrosis, depending on the
extent of oxidative stress. Superoxide was not induced in HepG2
cells following exposure to tolvaptan and its metabolites, DM-
4103, or DM-4107, as indicated by the dihydroethidium (DHE) flu-
orescence assay (Supplementary Figure 3-1). Experimental
details are provided in Supplementary File 3. Because no ROS
production was observed experimentally with DHE, the DILIsym
parameter values for tolvaptan did not include ROS production.
Pharmacokinetic modeling. The PBPK sub-model was parameter-
ized in order to predict the dynamics of orally dosed tolvaptan,
DM-4103, and DM-4107, in humans in both liver and blood. The
goal of the model parameterization was to represent the range
of observed concentrations for these 3 molecules in healthy
subjects and ADPKD patients. Initially, the PBPK sub-model was
parameterized based on data from healthy subjects with the
understanding that it would be adjusted if necessary to repro-
duce the range of plasma parent concentrations for ADPKD
patients.
Specific data used in optimization and validation of the
PBPK sub-model are listed in Table 1. The PBPK sub-model was
optimized with single-dose simulations of 30, 60, and 120 mg, as
well as a 7-day simulation of 60 mg daily dosing, and a 5-day
simulation of both 30 and 300 mg daily dosing; these simulated
dosing regimens were selected in order to match the protocols
for the clinical trials listed in Table 1. The parent and metabo-
lites were all fit at once using the same optimization routine,
which was a genetic algorithm using a least-squares fit to the
plasma data as the fitness function. The data to which the
model was optimized was weighted so that data for tolvaptan,
DM-4103, and DM-4107 had equal weight. The optimization also
included the total compound liver-blood ratio measured in the
rat whole-body autoradiography study (Furukawa et al., 2011) in
order to ensure relatively accurate liver exposure. Renal clear-
ance of unchanged parent drug was assumed to be<5% of the
total tolvaptan clearance, which is near the range suggested by
the experimental data (Shoaf et al., 2007).
Parameters that were employed in optimizing the PBPK sub-
model are listed in Table 2. These parameters include biliary
and renal clearance values for all chemical species, metabolism
maximum velocity (Vmax) values for both DM-4103 and DM-
4107, and distribution parameters for all chemical species.
FIG. 1. The effect of 24 h treatment of tolvaptan, DM-4103 and DM-4107 on basal
mitochondrial respiratory function (fmoles O2/min/cell) in HepG2 cells. Cells
were treated with control media or compound in a 5-point dose response regi-
men (tolvaptan at: 0.01, 0.1, 1, 20, and 50 mM or DM-4103 or DM-4107 at: 1, 20, 50,
100 and 200 mM) for 24 h prior to respirometry experiments. Oxygen consump-
tion rate (OCR) results were normalized to cell number. Data are presented as
the average6SEM for 3 independent experiments. Statistical significance is
denoted by an asterisk (* P  .05) for one-way ANOVA with Dunnett’s multiple
comparison test to compare each concentration to control for a given com-
pound. Two-way ANOVAs with a Bonferonni multiple comparison test was used
to compare compounds: #P  .05 (DM-4103 vs DM-4107); @ P  .05 (tolvaptan vs
DM-4103); & P  .05 (tolvaptan vs DM-4107).
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Simulated population creation. SimPops were used to understand
the role of inter-individual variability in tolvaptan-mediated
hepatotoxicity and to identify particular susceptibility factors.
The process used to generate tolvaptan-specific SimPops is sim-
ilar to the process described for troglitazone in previous
DILIsym work (Yang et al., 2015). The variability in parameters
specific to tolvaptan exposure in each case was superimposed
upon the existing Human_mito_BA_v3A_6 SimPops included
with DILIsym v3B. This SimPops covers variability in both bile
acid transport and mitochondrial function. Notably, this
SimPops features 17 simulated patients that were designed to
exhibit mitochondrial impairment similar to that observed in
NASH patients (Pe´rez-Carreras et al., 2003). As a result, the
SimPops for this project included 229 individuals with variabil-
ity in exposure parameters, bile acid transport parameters, and
mitochondrial parameters. Using this method,2 SimPops were
created: a Renally Sufficient SimPops and a Renally Impaired
SimPops.
The simulated human healthy volunteer population (the
Renally Sufficient SimPops) was designed to recapitulate
the range of tolvaptan exposures observed in healthy subjects.
The PBPK sub-model for this SimPops was constructed
using the parent and metabolite time course data for single
30 mg dose; single 60 mg dose; and single 120 mg dose; and for
repeat doses of 60 mg for 7 days, and 30 and 300 mg for 5 days
(Table 1). As described above, the collective clinical data set was
selected to provide a similar number of comparator studies for
each of the 3 molecular species for the single dose case (tolvap-
tan, DM-4103, DM-4107), and to include both single and repeat
dose studies within the optimization scheme. Several protocols
not used in the optimization scheme were employed to validate
the PBPK parameter values identified by the optimization
scheme. The test protocols included data for 15, 30, and 60 mg
single doses from clinical trials (Table 1). Finally, 90/30 mg split
daily dosing was simulated in this population to compare the
range of simulated tolvaptan plasma concentrations against
the range of measured concentrations in ADPKD patients in
90/30 mg split daily dosing trials (Boertien et al., 2013;
NCT01210560) in order to determine its validity for representing
the ADPKD patient population.
To simulate certain extreme ADPKD exposure profiles that
were not reproduced by the Renally Sufficient SimPops, a
Renally Impaired SimPops was developed. Tolvaptan PBPK
parameters that were assigned different ranges in the Renally
Impaired SimPops based on their relationship to renal impair-
ment are listed in Table 3. For example, CYP-mediated metabo-
lism decreased in renal impairment (Michaud et al., 2008). The
parameter ranges for the Renally Impaired SimPops were opti-
mized using PK data (156-04-001, 30 mg daily in ADPKD subjects,
data on file, Table 1) in which tolvaptan plasma concentrations
TABLE 1. Concentration Data Used in the Optimization and Validation of the Baseline DILIsym PBPK Sub-Model for Tolvaptan
Analytes Oral Dose (mg) DILIsym Use Protocol/Reference
Parent 30a PBPK Optimization; (Shoaf et al., 2012a)b
DM-4103 Baseline Human,
DM-4107 Renally Sufficient SimPops
Parent 60a PBPK Optimization; 156-05-256
DM-4103 Baseline Human, (data on file)b
DM-4107 Renally Sufficient SimPops
Parent 120a,c PBPK Optimization; (Shoaf et al., 2007)bd
DM-4107 Baseline Human,
Renally Sufficient SimPops
Parent 30, 300 qd 5d PBPK Optimization; 156-03-245
– Baseline Human, (data on file)b
– Renally Sufficient SimPops
Parent 60 qd 7d PBPK Validation; (Van Wart et al., 2013)b
DM-4103 Renally Sufficient SimPops
DM-4107
Parent 15 PBPK Validation; 156-12-202
– Baseline Human (data on file)b
–
Parent 30a,c PBPK Validation; (Shoaf et al., 2012b)b
DM-4103 Baseline Human
DM-4107
Parent 90/30 PBPK Validation; (Boertien et al., 2013)e
– split daily 7d Renally Impaired SimPops
–
Parent 90/30 PBPK Validation; NCT01210560
– split daily 7d Renally Impaired SimPops (data on file)e
–
Parent 30 PBPK Optimization; 156-04-001
– Renally Impaired SimPops (data on file)e
–
aUsed in Figure 2.
bTrial enrolled healthy subjects.
cTwo single doses separated in time.
dThe washout period between doses was insufficient to allow for full clearance of DM-4103, complicating the use of the DM-4103 data.
eTrial enrolled subjects with ADPKD.
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were markedly higher than those observed in the non-ADPKD
PK data. Whereas this trial was conducted with ADPKD patients
with preserved renal function, the data demonstrated the high-
est maximum concentration (Cmax) relative to tolvaptan dose of
any steady-state ADPKD clinical trial. The Renally Impaired
SimPops was validated by simulating 90/30 mg split daily dosing
and comparing the results against tolvaptan concentration data
from ADPKD patients with moderate to severe renal dysfunc-
tion (defined by an estimated glomerular filtration rate (eGFR)
of 30–60 mL/min/1.73 m2 and eGFR<30 mL/min/1.73 m2, respec-
tively) given 90/30 mg tolvaptan split daily dosing (Boertien
et al., 2013; NCT01210560).
Toxicity simulations. In general, tolvaptan has been regarded as
safe based on clinical experience in healthy subjects as well as
in patients with hyponatremia, including patients with heart
failure. Based on tolvaptan clinical trials for heart failure, a dos-
age regimen of 60 mg daily for 60 days was selected as a nega-
tive control that was not expected to cause hepatotoxicity.
Tolvaptan-associated liver safety signals initially were
reported in ADPKD Phase III trials in which chronic tolvaptan
treatment was being evaluated for its ability to slow disease
progression (Torres et al., 2012). Patients were administered tol-
vaptan as 45/15, 60/30, or 90/30 mg split daily doses separated
by 8 h. The highest dose was of the greatest interest because the
3 patients with severe liver injury (ie, that qualified as Hy’s Law
cases) were administered the 90/30 mg split daily doses
(Watkins et al., 2015). The ADPKD Phase III trials and follow-on
studies were conducted over years; one might therefore expect
the simulation studies to be conducted over years. However, the







Comp_W_bil_cla Tolvaptan biliary clearance 0.5 CYP activity impaired in uremic patientsb;
biliary clearance used to describe tolvaptan
metabolism to other metabolites
Comp_W_renal_cl Tolvaptan renal clearance 0.375 Impaired renal function
CompW_Met_A_renal_cl DM-4103 renal clearance 0.375 Impaired renal function
CompW_Met_B_renal_cl DM-4107 renal clearance 0.375 Impaired renal function
Vmax_CompW_Met_A DM-4103 generation Vmax 0.5 CYP activity impaired in uremic patients
a
Vmax_CompW_Met_B DM-4107 generation Vmax 0.5 CYP activity impaired in uremic patients
a
Body_mass Body mass 0.926 ADPKD patients more predominantly female
aComp W¼Compound W, a generic structure within DILIsym whose parameter values can be customized to represent the compound of interest.
bMichaud et al. (2008) reports reduction of CYP expression in vitro as a result of incubation with uremic serum; Kirch et al. (1984) reports that non-renal clearance can
be increased as much as 7-fold in individuals with moderate to severe renal impairment.
TABLE 2. Parameters Optimized to Data in the DILIsym PBPK Sub-Model for Tolvaptan.
Parameter Optimized in PBPK Sub-Model Fitting Process Optimized Parameter Value Units
Tolvaptan blood:plasma ratio 0.6 Dimensionless
Tolvaptan muscle:blood ratio 0.287 Dimensionless
Tolvaptan gut:blood ratio 0.592 Dimensionless
Tolvaptan biliary clearance 5.687 mL/h/kg0.75
DM-4103 biliary clearance 135.6 mL/h/kg0.75
DM-4107 biliary clearance 10.7 mL/h/kg0.75
DM-4103 fraction unbound in plasma 0.0245 Dimensionless
Tolvaptan liver:blood ratio 38.76 Dimensionless
DM-4103 liver:blood ratio 0.262 Dimensionless
DM-4107 liver:blood ratio 1.25 Dimensionless
DM-4107 fraction unbound in plasma 0.146 Dimensionless
Tolvaptan renal clearance 85.43 mL/h/kg0.75
DM-4103 volume of distribution 1210 mL/kg
DM-4107 volume of distribution 335 mL/kg
Tolvaptan fraction unbound in plasma 0.391 Dimensionless
Tolvaptan absorption from gut Vmax 69.19 mg/h
Tolvaptan-DM-4103 metabolism Km 8.60  107 mol/mL
Tolvaptan-DM-4107 metabolism Km 1.00  109 mol/mL
Tolvaptan other tissue:blood ratio 0.414 Dimensionless
Tolvaptan absorption from gut Km 0.0025 mg
Tolvaptan-DM-4103 metabolism Vmax 5.48  104 mol/h/kg0.75
Tolvaptan-DM-4107 metabolism Vmax 2.56  107 mol/h/kg0.75
Tolvaptan excretion from gut rate constant 0.4483 1/h
DM-4103 renal clearance 2.41 mL/h/kg0.75
DM-4107 renal clearance 934.3 mL/h/kg0.75
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occurrence of hepatotoxicity within DILIsym is asymptotic by
6 months. Briefly, simulated hepatotoxicity emerges from the
combination of hepatic exposure, mechanisms of toxicity, and
inter-individual variability in both. With chronic dosing of most
drugs, steady-state levels are typically reached within weeks.
Mitochondrial toxicity manifests rapidly (ie, within weeks). Bile
acid toxicity may manifest more slowly (ie, over months) as it is
dependent on the rate of bile acid accumulation, which is itself
dependent on the strength and type of transporter inhibition.
Further, DILIsym is a mechanistic model, meaning that stochas-
tic events will not alter the dynamics described above.
Therefore, a 90/30 mg split daily dosage regimen was simulated
for 180 days. The results were analyzed to illuminate the effect
of longer treatment duration on simulated hepatotoxicity and
compared against Phase III trials conducted over years.
Tolvaptan dosing was simulated at 60 mg daily for 60 days
and 90/30 mg split daily dosing for 180 days to investigate hepa-
totoxicity using the Renally Sufficient SimPops. Simulated hep-
atotoxicity following 90/30 mg split daily dosing for 180 days
was investigated subsequently to determine the relative impor-
tance of each toxicity mechanism and each molecular contribu-
tor to toxicity. The 90/30 mg split daily dosage regimen also was
simulated for 4 different scenarios, sequentially omitting one
potential mechanistic contributor to toxicity at a time: bile acid
transporter inhibition effects, mitochondrial dysfunction
effects, all effects due to the parent drug (tolvaptan), and all
effects due to DM-4103. DM-4107 exhibited no toxic effects and
so was not included in this analysis. These Mechanistic
Investigation Simulations, listed in Table 4, evaluated the
importance of each toxicity element to the overall DILI behavior
of drug treatment.
Because the Renally Impaired SimPops was designed to rep-
resent certain exposure-related aspects of ADPKD patients (ie, a
PBPK sub-model optimized for the highest levels of exposure
observed in ADPKD patients), all investigations with this
SimPops were conducted using the 90/30 mg split daily dosage
regimen for 180 days. Mechanistic Investigative Simulations as
described in the previous paragraph were conducted in the
Renally Impaired SimPops.
Unlike the clinical trials, the DILIsym simulations did not
include physician judgment or protocol-driven criteria to
increase monitoring and/or to halt treatment when ALT eleva-
tions exceeded pre-specified thresholds. Implementing such a
protocol in the SimPops simulations was unnecessary for the
purpose of identifying simulated individuals at risk for hepato-
toxicity and investigating the susceptibility of those individuals
to toxicity. Thus, in some cases, the magnitude of the simulated
liver injury exceeded what was observed in patients whose tol-
vaptan treatment might have been interrupted in response to
liver signals.
Susceptibility factor analysis. In order to identify potential sus-
ceptibility factors, a covariate analysis was performed with the
simulation results from the Renally Sufficient and Renally
Impaired SimPops (90/30 mg split daily doses for 180 days).
Parameters that were varied to create the simulated individuals
within the SimPops (Table 5) were used as independent varia-
bles, and simulated ALT elevations or simulated loss of liver
ATP were used as dependent variables in a covariate analysis.
Parameters that correlated with ALT elevations and loss of liver
ATP at P values<.05 were identified as potential susceptibility
factors. Covariate analysis was performed using JMP 9 (SAS,
Cary, NC).
A further analysis of DILIsym outputs was performed in
order to determine which outputs could suggest potential on-
treatment biomarkers of injury due to tolvaptan. Simulated
individuals with tolvaptan-mediated transaminase elevations
(defined by ALT elevations greater than 3 times ULN) developing
after 2 weeks of simulated tolvaptan dosing were identified
from both the Renally Sufficient and Renally Impaired SimPops.
The DILIsym outputs during the first 2 weeks of dosing (ie,
before the onset of hepatotoxicity) were analyzed for the ability
of each output to differentiate individuals who developed DILI
from those who did not. The area under the receiver-operating
characteristic curve (AUROC) was calculated for each output
and also for each pair of outputs, and these values were used to
rank order the outputs as putative biomarkers or biomarker
indicators (Liu and Zhou, 2013; Vexler et al., 2014).
RESULTS
PBPK Modeling—Baseline Human
The DILIsym simulations of tolvaptan, DM-4103 and DM-4107
concentrations in renally sufficient individuals were intended
to capture a range of exposures consistent with those observed
in non-ADPKD individuals and ADPKD patients with well-
preserved renal function. The DILIsym PBPK sub-model was
optimized to single- and multiple-dose healthy subject data
listed in Table 1.
PBPK Modeling—SimPops Results
The ability of the simulations to cover the measured range of
tolvaptan and metabolite concentrations in healthy subjects
was assessed by simulating tolvaptan dosage regimens with the
TABLE 4. List of Mechanistic Investigation Simulations and the Mechanisms that Were Turned On and Off for Each Simulation of Tolvaptan
Administered 90/30 mg Daily for 180 Days
Mechanistic Investigation Simulation Name Mechanisms Mechanism(s)
Ona Off
– TVP: BSEPi, NTCPi, ETCi None
DM-4103: BSEPi, NTCPi, ETCi
ETCi-Off TVP: BSEPi, NTCPi ETCi
DM-4103: BSEPi, NTCPi
BA-Off(BSEPi, NTCPi) TVP: ETCi BAb
DM-4103: ETCi (BSEPi, NTCPi)
TVP-Off DM-4103: BSEPi, NTCPi, ETCi TVP
DM-4103-Off TVP: BSEPi, NTCPi, ETCi DM-4103
aTVP is tolvaptan; DM-4103 is a metabolite of tolvaptan; BSEPi is inhibition of BSEP; NTCPi is inhibition of NTCP; ETCi is inhibition of ETC.
bBA is bile acids; turning this mechanism off means removing both BSEP and NTCP inhibition.
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PBPK optimization solution in the Renally Sufficient SimPops.
The Renally Sufficient SimPops simulation results extend across
the range of plasma concentrations in the clinical data for the
30, 60, and 120 mg single dose studies from healthy subjects
used to construct the Renally Sufficient SimPops (Figure 2).
To determine the ability of simulations to cover the meas-
ured range of tolvaptan concentrations in ADPKD patients, the
simulation results in the Renally Sufficient SimPops were com-
pared with PK data obtained from ADPKD patients treated with
a 90/30 mg split daily dose of tolvaptan (Boertien et al., 2013). As
shown in the comparison to the validation data in Figure 3, the
range of predicted variability in the Renally Sufficient SimPops
reproduced most of the range of tolvaptan plasma concentra-
tions observed in the ADPKD clinical trial, though the peak con-
centrations occur at a slightly later time and the highest
measured concentrations were not reproduced. Metabolites
were not measured as a part of this trial’s protocol.
To confirm that PBPK parameter values from the Renally
Impaired SimPops met the intended objective of representing
patients with relatively high exposure, seen in some patients
with ADPKD, that were not represented by the Renally
Sufficient SimPops (above), simulation results were compared
with the clinical data from studies where ADPKD patients were
given 90/30 mg split daily dosing. In the 90/30 mg split daily dos-
ing study (Boertien et al., 2013), patients were grouped according
to renal function (eGFR> 60 mL/min/1.73 m2, eGFR 30–60 mL/
min/1.73 m2, eGFR< 30 mL/min/1.73 m2), which allowed a com-
parison to patients with moderate to severe renal impairment
(ie, eGFR 30–60 mL/min/1.73 m2 and eGFR< 30 mL/min/1.73 m2).
Simulation results of tolvaptan from the Renally Impaired
TABLE 5. List of Parameters Included in the SimPops Used for This Investigation and The Ranges For Each Parameter Relative to Their Average
Values




ATP_decr_necrosis_Vmax Vmax for ATP decrement to necrosis 49.1–147% 49.1–147%
Basal_Stdzd_MitoETC_Flux Basal ETC flux 25.7–175% 25.7–175%
Body_mass Body mass 63.0–139% 69.2–133%
CDCA_amidation_Vmax CDCA amidation Vmax 6.65–171% 6.65–171%
CDCAamide_baso_Vmax CDCA-amide basolateral transport Vmax 10.7–459% 10.7–459%
CDCAamide_canal_Vmax CDCA-amide canalicular transport Vmax 27.1–168% 27.1–168%
CDCAamide_uptake_Vmax CDCA-amide uptake transport Vmax 26.6–208% 26.6–208%
CompW_Met_A_bil_cl DM-4103 biliary clearance 45.4–131% 56.4–153%
CompW_Met_A_renal_cl DM-4103 renal clearance 46.6–136% 18.1–121%
CompW_Met_B_bil_cl DM-4107 biliary clearance 50.6–139% 53.1–132%
CompW_Met_B_renal_cl DM-4107 renal clearance 93.7–112% 15.6–126%
Comp_W_bil_cl Tolvaptan biliary clearance 54.4–144% 17.4–126%
Comp_W_renal_cl Tolvaptan renal clearance 57.9–135% 20.1–124%
HGF_regen_Vmax Hepatocyte regeneration Vmax 49.1–147% 49.1–147%
LCA_synthesis_Vmax LCA synthesis Vmax 6.56–1804% 6.56–1804%
LCAamide_sulfation_Vmax LCA-amide sulfation Vmax 13.5–349% 13.5–349%
LCAsulfate_canal_Vmax LCA-sulfate canalicular transport Vmax 7.18–181% 7.18–181%
LCAsulfate_uptake_Vmax LCA-sulfate uptake transport Vmax 14.6–376% 14.6–376%
Resp_Reserve_Scalar Respiratory reserve capacity 54.7–154% 54.7–154%
Vmax_CompW_Met_A DM-4103 formation Vmax 37.4–231% 8.40–243%
Vmax_CompW_Met_B DM-4107 formation Vmax 37.4–231% 8.40–243%
Vmax_Comp_W_ab Tolvaptan absorption from gut Vmax 52.4–151% 45.5–132%
canal_reg_scale FXR-mediated canalicular bile acid transporter regulation scaling factor 7.33–146% 7.33–146%
uptake_reg_scale FXR-mediated bile acid uptake transporter regulation scaling factor 0–284% 0–284%
FIG. 2. Comparison between single dose clinical data for 30 mg, dark red, 60 mg, cyan, and 120 mg, dark green (Table 1), and range of Renally Sufficient SimPops simulation
results for (a) tolvaptan plasma concentrations; (b) DM-4103 plasma concentrations (note: data from the 120 mg study were unavailable for this analyte; see Table 1); (c)
DM-4107 plasma concentrations. Dark circles represent the average of the clinical data; stars represent the maximum and minimum value measured in the clinical trial.
Simulation results for the 30 mg study are in red, simulation results for the 60 mg study are in blue, and simulation results for the 120 mg study are in green.
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SimPops generally spanned the range measured for these
patients with renal dysfunction in the validation data set
(Figure 4). The comparison demonstrated that the Renally
Impaired SimPops yielded tolvaptan plasma concentrations
that met or exceeded the highest concentrations observed
within the clinical trial (Boertien et al., 2013).
Toxicity Parameters
In vitro laboratory investigations were conducted to assess the
potential of tolvaptan, DM-4103, or DM-4107 to induce mito-
chondrial dysfunction and to elicit oxidative stress. Previous
research had assessed the potential of tolvaptan, DM-4103, and
DM-4107 to inhibit the bile acid transporters BSEP and NTCP
(Slizgi et al., 2016). These data demonstrated that both tolvaptan
and DM-4103 inhibited BSEP and NTCP bile acid transporters.
Mitochondrial respiration data generated in support of this proj-
ect demonstrated that both tolvaptan and DM-4103 induced
mitochondrial dysfunction (Figure 1). DM-4107 did not influence
bile acid transporters or mitochondria, and none of the 3
chemical species induced oxidative stress as measured by cyto-
solic superoxide levels in HepG2 cells (Supplementary File 3).
The bile acid transporter inhibition constants were used
directly in DILIsym (Table 6). BSEP inhibition was competitive
based on the experimental Ki data (Slizgi et al., 2016). Because
only NTCP IC50 data were available, either competitive or non-
competitive inhibition could be assumed. For the same inhibi-
tion constant, competitive inhibition will result in more bile
acid uptake than non-competitive inhibition. To allow for the
greatest possible uptake (ie, the most potential toxicity), NTCP
inhibition was assumed to be competitive. It should be noted
that the actual level of bile acid accumulation that occurs is
dependent on the net effect of tolvaptan and metabolites on the
various transporters, as well as the activity of adaptive mecha-
nisms such as farnesoid X receptor (FXR) activation.
The cellular respiration experimental data were used to opti-
mize the MITOsym ETC inhibition parameters for tolvaptan and
DM-4103. As described in the methods, both the nominal media
concentration and the predicted intracellular compound con-
centration were considered for the optimization. As shown in
Figure 5, the predicted intracellular compound concentration
(based on PBPK simulation results) was markedly higher than
the nominal media concentration for tolvaptan, but not DM-
4103. This difference was reflected in the optimized ETC inhibi-
tion parameter value for tolvaptan, but not DM-4103. The
MITOsym parameters derived when allowing the intracellular
compound concentration to reflect the PBPK simulation results
were transformed to DILIsym parameters (Table 6) and used for
the toxicity simulations. It should be noted that the parameter
values for mechanisms of hepatotoxicity for tolvaptan and
metabolites are independent of the simulated patients and do
not vary whether the simulations are conducted in the Renally
Sufficient or the Renally Impaired SimPops.
Toxicity Investigations
To increase confidence that the DILIsym parameter values for
tolvaptan reasonably captured “safe” tolvaptan scenarios (in
addition to the DILI scenarios of interest), the 60 mg daily dose
for 60 days tolvaptan dosage regimen was simulated in the
Renally Sufficient SimPops. Nearly all simulated individuals
(n¼ 228/229) were predicted to have normal ALT levels through-
out; one simulated individual developed an ALT elevation
(Table 7). The one simulated individual with an ALT elevation
was identified as one of the aforementioned individuals with
mitochondrial activity parameters characteristic of NASH
patients. The fact that the other 16 NASH-like simulated individ-
uals did not develop hepatotoxicity indicates that toxicity was
not solely attributable to mitochondrial activity. Rather, this par-
ticular simulated individual also possessed bile acid transport
characteristics in the lower range of normal, resulting in suscept-
ibility to tolvaptan-mediated hepatotoxic mechanisms.
When the 90/30 mg split daily dosage regimen was simulated
for 180 days in the Renally Sufficient SimPops, 7.9% of simulated
individuals developed ALT elevations>3x ULN. This can be com-
pared against the clinical observation of 4.4% of patients with ALT
elevations>3x ULN (Watkins et al., 2015). As noted previously, the
DILIsym simulations did not include physician judgment or
protocol-driven criteria to increase monitoring and/or to halt
treatment when ALT elevations exceeded pre-specified thresh-
olds. Also, there were more simulated Hy’s Law cases denoting
serious liver injury (ALT>3x ULN and bilirubin>2x ULN) (6.5%)
than were observed clinically (0.2%) (Watkins et al., 2015). The
average simulated time to peak ALT value was 2.5 months, which
FIG. 3. Comparison between Renally Sufficient SimPops and day 21 tolvaptan
plasma concentrations after 90/30 mg split daily dosing (Boertien et al., 2013).
The clinical data are represented by symbols (black squares) whereas the simu-
lation results for individual simulated patients are represented by solid lines.
FIG. 4. Comparison between Renally Impaired SimPops and day 21 tolvaptan
plasma concentrations after 90/30 mg split daily dosing (Boertien et al., 2013).
The clinical data are represented by symbols (black squares) whereas the simu-
lation results for individual simulated patients are represented by solid lines.
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TABLE 6. DILIsym Toxicity Parameter Values for Tolvaptan Toxicity Simulations




Tolvaptan BSEP inhibition Ki_noncomp_BSEP_CompW BSEP non-competitive inhibition constant for
Compound W
0.0154a mg/mL
Tolvaptan NTCP inhibition Ki_NTCP_CompWb NTCP competitive inhibition constant for Compound
W
0.0187a mg/mL
Tolvaptan ETC inhibition MitoS_ETC_inhib_CompW Coefficient to quantify ETC inhibition based on com-
pound/metabolite levels in the liver
1.09  106 mol/mL
DM-4103 BSEP inhibition Ki_BSEP_CompW_MetAb BSEP competitive inhibition constant for Compound
W metabolite A
0.002a mg/mL
DM-4103 NTCP inhibition Ki_NTCP_CompW_MetAb NTCP competitive inhibition constant for Compound
W metabolite A
0.0071a mg/mL
DM-4103 ETC inhibition MitoS_ETC_inhib Coefficient to quantify ETC inhibition based on com-
pound/metabolite levels in the liver
9.38  109 mol/mL
aValues are unit converted to mg/mL from mM IC50 values. The values reflect preliminary IC50 values available at the time the DILIsym modeling was conducted. The
values are numerically very similar to the final values as reported recently (Slizgi et al., 2016). The numerical differences do not have any effect on the overall
conclusions.
bFor competitive inhibition of a given transporter, 6 parameters are populated. The parameters represent the different bile acid species in DILIsym (bulk bile acids, LCA,
LCA amide, LCA sulfate, CDCA, CDCA amide). For example, competitive NTCP inhibition by tolvaptan is represented by using the inhibition constant for the following
parameter values: (1) Ki_NTCP_CompW, (2) LCA_uptake_Ki_CompW, (3) LCAamide_uptake_Ki_CompW, (4) LCAsulfate_uptake_Ki_CompW, (5) CDCA_uptake_Ki_CompW,
and (6) CDCAamide_uptake_Ki_CompW.
FIG. 5. Comparison of simulation results and in vitro data for tolvaptan- and DM-4103-induced inhibition of HepG2 oxygen consumption rate. Simulations were con-
ducted in MITOsym and were used to identify parameter values for compound-mediated ETC inhibition that permit simulations to reproduce the in vitro data. The
intracellular compound concentration was either assumed to be equivalent to the nominal media concentration or was estimated based on the liver:plasma ratio
derived from simulations using the PBPK sub-model. MITOsym parameter values identified with the estimated intracellular compound concentrations were the ones
translated to DILIsym and used for toxicity simulations.
TABLE 7. Frequency of Simulated ALT Elevations in the Renally Sufficient SimPops
Toxicity Mechanisms Dose Simulated Simulated
ALT >3x ULN Hy’s Law Cases
Alla 60 mg daily, 60 days 1/229 1/229
All 90/30 mg daily, 180 days 18/229 15/229
TVP-Offb 90/30 mg daily, 180 days 0/229 0/229
DM-4103-Off 90/30 mg daily, 180 days 5/229 5/229
ETCi-Off 90/30 mg daily, 180 days 9/229 6/229
BA-Off 90/30 mg daily, 180 days 0/229 0/229
aAll refers to simulations in which both tolvaptan and DM-4103 mediate toxicity and both bile acid and mitochondrial toxicity mechanisms are active.
bThese simulation names refer to the Mechanistic Investigation Simulation names listed in Table 4. Mechanisms present and not present for each simulation can be
found there.
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is early relative to the susceptible range of 3–18 months for ALT
elevations in ADPKD patients (Watkins et al., 2015).
The relative importance of parent vs. metabolite and bile acid
versus mitochondrial toxicity were investigated using
Mechanistic Investigation Simulations (see Materials and
Methods). This exploration suggested that both mechanisms of
hepatotoxicity and both molecular species were involved in the
observed toxicity (Table 7). Whereas the simulations with the
complete set of parameter values (all molecular species active
and both mechanisms active) yielded 18/229 simulated patients
with liver injury, removing bile acid-mediated toxicity
(Simulation BA-Off) or parent tolvaptan-mediated toxicity (TVP-
Off) eliminated the simulated hepatotoxicity altogether (0/229
simulated patients with liver injury), suggesting that these 2
elements are major contributors to the hepatotoxicity. The
DM-4103-Off and ETCi-Off simulations, which remove DM-4103
toxicity or mitochondrial toxicity respectively, only attenuated
the simulated toxicity, suggesting that these elements may also
contribute to potential liver injury but to a lesser extent (Table 7).
Together, these Mechanistic Investigation Simulations indicated
that tolvaptan-mediated toxicity is likely to be multifactorial.
The results from the hepatotoxicity simulations conducted
with the Renally Impaired SimPops are listed in Table 8. For the
180 days, 90/30 mg split daily dosage regimen simulation, the
incidence rate of simulated ALT elevations (70/229) was much
higher than the 18/229 predicted for the Renally Sufficient
SimPops, indicating that changes in tolvaptan disposition simi-
lar to that observed in renal dysfunction could increase the risk
of tolvaptan-mediated hepatotoxicity. Increased plasma expo-
sure due to renal dysfunction could result from disease progres-
sion; however, this hypothesized relationship between disease
progression and susceptibility to hepatotoxicity requires clinical
validation, as prior clinical studies were not designed to address
this question. Nevertheless, it was desirable to have a popula-
tion wherein the incidence rate was inflated; more individuals
with ALT elevations permitted a more robust susceptibility fac-
tor analysis and on-treatment biomarker analysis than what
would have been possible with the low number of individuals
with ALT elevations from the Renally Sufficient SimPops alone.
The time required for the simulated individuals to reach peak
ALT averaged one month. Faster timing in the Renally Impaired
SimPops relative to the Renally Sufficient SimPops was attrib-
uted to increased tolvaptan exposure in these simulations.
The Mechanistic Investigation Simulation results for the
Renally Impaired SimPops listed in Table 8 demonstrated a pat-
tern similar to the Renally Sufficient SimPops. The BA-Off and
TVP-Off simulations, which eliminated bile acid-mediated tox-
icity and parent tolvaptan-mediated toxicity, had the most pre-
cipitous decline in ALT elevation frequency relative to the case
where all mechanisms were present; however, the DM-4103-Off
simulation and the ETCi-Off simulation produced notably fewer
ALT elevations as well. These results strongly suggest that the
injury observed in the clinic is multifactorial in nature, with bile
acid transport inhibition by tolvaptan the primary contributor
among the mechanisms included in this model.
Susceptibility Factors
Covariate analysis was conducted to identify patient parameter
values that predicted tolvaptan-mediated DILI prior to treat-
ment initiation. Such parameters have the potential to inform
the search for screening assays to prospectively identify
patients at risk for tolvaptan-mediated DILI. In particular, this
analysis may identify factors that predispose patients with
ADPKD to liver toxicity from tolvaptan. The results of the cova-
riate analysis for the Renally Sufficient SimPops are shown in
Table 9. Of the 23 parameters varied in the SimPops, 4 showed a
statistically significant correlation with both ALT elevations
and liver ATP decrement. Two of these parameters are related
to mitochondrial function (basal ETC flux and respiratory
reserve scaling factor), one of these parameters is related to bile
acid transport (CDCA-amide canalicular Vmax), and the other is
related to drug distribution (body mass). The correlation coeffi-
cient is strongest for the mitochondrial function parameters,
followed by the bile acid transport parameter.
The results for the Renally Impaired SimPops are shown in
Table 10. For this SimPops, there were 6 parameters that
showed a statistically significant correlation with both meas-
ures of injury: 2 mitochondrial function parameters (basal ETC
flux and respiratory reserve scaling factor), 3 bile acid transport
parameters (CDCA-amide canalicular Vmax, CDCA amidation
Vmax, and canalicular regulation scaling factor), and one drug
distribution parameter (metabolite generation Vmax). These
parameters include the 2 mitochondrial function parameters
and the bile acid transport parameter identified as correlates of
injury in the Renally Sufficient SimPops; indeed, these 3 param-
eters—basal ETC flux, respiratory reserve capacity, and CDCA-
amide canalicular transport Vmax—are the strongest correlates
of injury in the Renally Impaired SimPops as well.
The area under the receiver-operating characteristic curve
(AUROC) analysis was conducted to identify simulated patient
outputs that predict tolvaptan-mediated DILI prior to injury pre-
sentation. These outputs have the potential to inform the iden-
tification of patient-monitoring biomarkers to prospectively
identify patients at risk for tolvaptan-mediated DILI. The list of




Dose ALT >3x ULN Hy’s Law
All 90/30 mg daily, 180 days 70/229 66/229
TVP-Offa 90/30 mg daily, 180 days 3/229 0/229
DM-4103-Off 90/30 mg daily, 180 days 48/229 41/229
ETCi-Off 90/30 mg daily, 180 days 23/229 17/229
BA-Off 90/30 mg daily, 180 days 6/229 4/229
aThese simulation names refer to the Mechanistic Investigation Simulation
names listed in Table 4. Mechanisms present and not present for each simula-
tion can be found there.
TABLE 9. Results of Covariate Analysis for the Renally Sufficient
SimPops
Parametera Max ALT Min ATP
P-value R-valueb P-value R-valueb
Body mass .0408 0.1353 .0039 0.19
Basal ETC flux .0001 0.2541 <.0001 0.4189
CDCA-amide canalicular
Vmax
<.0001 0.2608 <.0001 0.2984
Respiratory reserve scaling
factor
.0003 0.2354 <.0001 0.3198
aOnly parameters meeting the statistical threshold of P < .05 correlation with
both dependent parameters are listed. Body mass is related to ADME; basal ETC
flux and respiratory reserve scaling factor are related to mitochondrial function;
CDCA-amide canalicular Vmax is related to bile acid transport.
bCorrelations were computed in JMP 9 (SAS, Cary, NC) using the Pearson’s
method.
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single DILIsym outputs that demonstrated an AUROC value
above 0.75 for early on-treatment prediction of ALT elevations
is shown in Table 11. Blood bile acids were predicted to be
potential biomarkers; several blood bile acid species, as well as
total blood bile acids, were predicted to be moderately good pre-
dictors of hepatic injury. Decreased bile acid efflux from the
liver, as would be measured by decreased fecal bile acids
(Kakiyama et al., 2014), was predicted to be an even better poten-
tial biomarker for future tolvaptan-mediated injury. DILIsym
predicted that electron transport chain activity would be the
best biomarker for injury susceptibility if a reliable test existed;
this is based on the fact that both increasing bile acid concen-
trations and ETC inhibition affect ETC activity. Combining 2
potential biomarkers did not improve the predicted quality of
the biomarkers in DILIsym.
DISCUSSION
About 228 of 229 simulated individuals in the Renally Sufficient
SimPops experienced no ALT elevation following treatment
with 60 mg tolvaptan daily for 60 days, suggesting that the
DILIsym parameter values for tolvaptan are consistent with the
overall safe clinical experience in healthy subjects and non-
ADPKD patients. The single simulated individual with an ALT
elevation had NASH-like liver biochemistry and was unlikely to
be representative of patients in the clinical trials. In contrast,
7.9% of simulated patients from the Renally Sufficient SimPops
treated with a 90/30 mg split daily dosage regimen experienced
ALT elevations. This is higher than the 4.4% observed in the piv-
otal ADPKD clinical trial (Watkins et al., 2015), and the difference
may be attributed to the absence within DILIsym of some com-
pensatory mechanisms. For example, DILIsym does not yet
include mitochondrial biogenesis, a response that has been
qualitatively but not quantitatively characterized (Han et al.,
2012). Because tolvaptan toxicity is mediated by direct mito-
chondrial toxicity and bile acid accumulation, which ultimately
also impacts mitochondria, the lack of compensatory mecha-
nisms may lead to overestimated liver injury. Despite this dif-
ference, reproducing largely safe responses for 60 mg qd and a
low frequency of injury for 90/30 mg split daily dosing without
further re-optimization of parameter values supports the con-
tention that DILIsym can incorporate PK and mechanistic data
in a clinically relevant manner. Mechanistic Investigation
Simulations indicated that both bile acid transporter inhibition
and mitochondrial dysfunction induced by tolvaptan and/or its
metabolites contribute to the observed liver injury in vivo.
Simulation of delayed onset in ALT elevations suggested that
these intrinsic mechanisms should be considered as plausible
contributors to the clinical observation of delayed liver injury.
The higher frequency of simulated ALT elevations in the
Renally Impaired relative to the Renally Sufficient SimPops sug-
gested that changes in tolvaptan and metabolite disposition as
observed in renal dysfunction could increase the risk of
tolvaptan-mediated hepatotoxicity. Notably, although the label
“Renally Impaired” was used to reflect the biological basis for
parameter selection, the PBPK optimization was conducted
against high exposure data measured in ADPKD patients with
preserved renal function (see Materials and Methods). It is plau-
sible to posit that higher plasma exposure is related to the
effects of renal impairment. These effects, however, do not
appear to be a major causal factor in liver injury. As the suscept-
ibility factor analysis pointed out, variability in parameters
related to renal impairment were not major contributors to the
simulated ALT elevations. The implication is that within the
clinically relevant dosing range, increased plasma tolvaptan
exposure is not readily predictive of potential toxicity on an
individual basis, but that increased exposure for an entire popu-
lation can reveal the underlying susceptibility of certain
patients within that population, leading to a potentially higher
overall rate of toxicity.
The Renally Impaired SimPops could also be considered a
proxy for disease progression; as ADPKD progresses, renal
capacity decreases, which would be expected to alter liver expo-
sure and/or function. Either may result in increased likelihood
TABLE 11. Results for DILIsym Outputs with an Area Under the
Receiver-Operating Characteristic Curve Score> 0.75
DILIsym Outputs AUROCa
Blood CDCA 0.809
Blood bulk BA 0.743
Blood CDCA-amide 0.739
Blood LCA 0.738
Bulk bile acid biliary efflux 0.859
Total bile acid biliary efflux 0.811
Midlobular ETC activity 0.901
Periportal ETC activity 0.888
Centrilobular ETC activity 0.877
Other individual blood bile acids (with scores<0.75) are listed for comparison
with CDCA.
aAUROC¼area under the receiver-operating characteristic curve.
TABLE 10. Results of Covariate Analysis for the Renally Impaired SimPops
Parametera Max ALT Min ATP
P-value R-valueb P-value R-valueb
Metabolite generation Vmax .0033 0.1936 .0068 0.178474
Basal ETC flux <.0001 0.32336 <.0001 0.372894
CDCA amidation Vmax .008 0.17472 .0226 0.150631
CDCA-amide canalicular Vmax <.0001 0.51093 <.0001 0.549344
Respiratory reserve scaling factor <.0001 0.2651 <.0001 0.295598
Canalicular regulation scaling factor .0333 0.14072 .0298 0.14364
aOnly parameters meeting the statistical threshold of P < .05 correlation with both dependent parameters are listed. Metabolite generation Vmax is related to ADME;
basal ETC flux and respiratory reserve scaling factor are related to mitochondrial function; CDCA-amide canalicular Vmax, CDCA amidation Vmax, and canalicular regu-
lation scaling factor are related to bile acid transport.
bCorrelations were computed in JMP 9 (SAS, Cary, NC) using the Pearson’s method.
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of toxicity. The tolvaptan pattern of hepatotoxicity includes
symptoms that appear up to 18 months after the initiation of
treatment in some patients; and it is tempting to speculate that
disease progression could contribute to the extremely long
latency to liver injury (Watkins et al., 2015). However, this
hypothesis remains untested as clinical studies referenced in
this work were not designed to address this question.
The factorial analysis predicted that both bile acid accumu-
lation and mitochondrial dysfunction contribute to tolvaptan-
mediated liver injury, and that both parent compound and DM-
4103 contribute to the toxicity as well. Multifactorial tolvaptan
hepatotoxicity is supported by a recent study that suggested
compounds inhibiting BSEP and inducing mitochondrial dys-
function were more associated with severe human DILI (Aleo
et al., 2014).
Notably, the predicted multifactorial nature of tolvaptan
hepatotoxicity stands in direct contrast to previous work using
DILIsym to identify the potential mechanisms of tolcapone-
induced hepatotoxicity (Longo et al., 2016). Tolcapone, like tol-
vaptan, is both a bile acid transporter inhibitor and an inducer
of mitochondrial dysfunction in vitro. However, only the mito-
chondrial dysfunction contributed to tolcapone hepatotoxicity.
The contrast between these 2 compounds demonstrates how
QSP modeling can add value to the results of in vitro assays by
placing their results in the proper biological context.
The susceptibility factor analysis indicated that whereas
increased exposure may reveal underlying susceptibility in
some patients, higher exposure alone cannot be considered a
risk factor for injury, and mechanistic markers of injury need to
be employed in order to prospectively identify patients at risk
for hepatotoxicity. However, none of the identified parameters
has a reliable, accepted test that can be used to determine the
value of this parameter in patients. The results, therefore, sug-
gest a need to develop new genetic or functional markers that
can assess baseline mitochondrial function and canalicular bile
acid transporter activity in the liver. The predicted multifacto-
rial nature of the injury also suggested that the identification of
at-risk individuals would likely require a combination of several
markers that can assess risk in terms of both bile acid transport
capability and mitochondrial function. Research to investigate
potential genetic markers is ongoing.
The late onset of clinically observed tolvaptan hep-
atotoxicity—between 3 and 18 months (Watkins et al., 2015)—
suggests that there is an opportunity to identify patients on-
treatment that are at increased risk of developing DILI before
traditional biomarkers are elevated and before patients present
with symptoms. Because DILIsym mechanistically represents
drug-induced changes in the liver and time to peak ALT was
often delayed, it was possible to mine the simulation results for
model outputs whose changes predict later hepatotoxicity.
These results, summarized above as on-treatment susceptibility
factors presented by simulated AUROC, suggested that novel or
emerging biomarkers that are mechanistically related to mito-
chondrial activity could be used to monitor patients. Bile acid
concentrations perform passably as biomarkers; however, the
inter- and intra-individual variability in plasma bile acid con-
centrations confounds their usage. To incorporate both mecha-
nisms, a more effective approach would be an on-treatment
measure of mitochondrial stress, because both bile acid accu-
mulation and electron transport chain inhibition stress the
mitochondria. The results presented here suggest that this
would be a promising area for investigation into novel bio-
markers of tolvaptan hepatotoxicity.
Whereas both mechanisms implicated by the in vitro assays
were shown to contribute to simulated in vivo toxicity, neither
plasma drug nor plasma metabolite concentrations emerged
from the AUROC analysis as viable biomarkers, either as indi-
vidual outputs or in combination with other outputs. This is
consistent with clinical observations suggesting that an individ-
ual’s exposure to tolvaptan or its metabolites is not a reliable
predictor of whether that individual will develop toxicity
(Watkins et al., 2015).
DILIsym tolvaptan simulations provided a biologically plau-
sible link between in vitro mechanistic data and human hepato-
toxicity, and allowed for identification of patient susceptibility
factors; however, there are a few discrepancies between the
results reported here and other previously reported findings.
First, there were more simulated severe cases than clinically
observed. It is likely that compensatory mechanisms like mito-
chondrial biogenesis described above not only affect the fre-
quency but also the severity of liver injury. Second, our data
demonstrated no induction of oxidative stress by tolvaptan or
its metabolites at the concentrations tested. Data from other
recently published tolvaptan data (Wu et al., 2015) showed that
concentrations of 60 lM and higher caused a significant
increase in ROS in HepG2 cells. They also showed minimal ROS
increases at concentrations lower than 60 lM, which were con-
sistent with results found from our study, as we did not test tol-
vaptan at concentrations higher than 50 lM. Interestingly, a
comparison of the in vitro data derived 24 h area under the curve
(AUC) media exposure of HepG2 cells to tolvaptan and the simu-
lated 24 h AUC tolvaptan exposure in the liver indicated that
liver exposure is<5% of the in vitro exposure needed to induce
oxidative stress. These data suggest that oxidative stress, as
reported by Wu et al. (2015), is unlikely to impact the conclu-
sions reported here. Finally, delayed onset DILI often is attrib-
uted to an adaptive immune response (Adams et al., 2010; Holt
and Ju, 2006). DILIsym does not yet include a representation of
the adaptive immune response. However, simulations illus-
trated that tolvaptan-mediated bile acid transporter inhibition
can result in delayed onset DILI, similar to what was reported
previously for troglitazone (Yang et al., 2015). The inclusion of
adaptive immunity might increase the simulated frequency of
hepatotoxicity but could be counter-balanced by the inclusion
of compensatory mechanisms described above. Also, there are
currently no clear data describing tolvaptan-specific T cell
responses. Taken together, it can be argued that DILIsym has
integrated the available tolvaptan data and our current under-
standing of DILI to provide in vivo plausibility for 2 mechanisms
of hepatotoxicity and direction for the pursuit of mechanistic
biomarkers.
In conclusion, the results presented herein illustrate how
DILIsym can be applied to better understand clinically observed
hepatotoxicity and prospectively inform patient susceptibility.
Efforts currently are underway to leverage these results in the
validation of biomarkers to identify individuals at risk for tol-
vaptan hepatotoxicity.
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